523 related articles for article (PubMed ID: 34373422)
21. Immune checkpoint inhibitors associated granulomatous small vessel vasculitis accompanied with tubulointerstitial nephritis: a case report.
Tominaga K; Takeuchi K; Takakuma S; Sakamoto E; Hatanaka S; Kajimoto Y; Toda E; Terasaki Y; Kunugi S; Terasaki M; Shimizu A
BMC Nephrol; 2023 Mar; 24(1):48. PubMed ID: 36894873
[TBL] [Abstract][Full Text] [Related]
22. New onset diabetes with ketoacidosis following nivolumab immunotherapy: A case report and review of literature.
Delasos L; Bazewicz C; Sliwinska A; Lia NL; Vredenburgh J
J Oncol Pharm Pract; 2021 Apr; 27(3):716-721. PubMed ID: 32723064
[TBL] [Abstract][Full Text] [Related]
23. Autoimmune hypophysitis secondary to therapy with immune checkpoint inhibitors: Four cases describing the clinical heterogeneity of central endocrine dysfunction.
Hartmann A; Paparoupa M; Volkmer BG; Rompel R; Wittig A; Schuppert F
J Oncol Pharm Pract; 2020 Oct; 26(7):1774-1779. PubMed ID: 32164491
[TBL] [Abstract][Full Text] [Related]
24. A case of nivolumab-induced acute-onset type 1 diabetes mellitus in melanoma.
Sakaguchi C; Ashida K; Yano S; Ohe K; Wada N; Hasuzawa N; Matsuda Y; Sakamoto S; Sakamoto R; Uchi H; Furue M; Nomura M; Ogawa Y
Curr Oncol; 2019 Feb; 26(1):e115-e118. PubMed ID: 30853818
[TBL] [Abstract][Full Text] [Related]
25. Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology Group.
Grimmelmann I; Momma M; Zimmer L; Hassel JC; Heinzerling L; Pföhler C; Loquai C; Ruini C; Utikal J; Thoms KM; Kähler KC; Eigentler T; Herbst RA; Meier F; Debus D; Berking C; Kochanek C; Ugurel S; Gutzmer R;
Eur J Cancer; 2021 May; 149():1-10. PubMed ID: 33812141
[TBL] [Abstract][Full Text] [Related]
26. Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report.
Fuu T; Iijima K; Kusama Y; Otsuki T; Kato H
J Med Case Rep; 2022 May; 16(1):193. PubMed ID: 35581611
[TBL] [Abstract][Full Text] [Related]
27. Acute-onset diabetes mellitus with ketoacidosis in a nivolumab-treated patient with hepatocellular carcinoma.
Harsch IA; Konturek PC
Wiad Lek; 2018; 71(5):945-948. PubMed ID: 30176620
[TBL] [Abstract][Full Text] [Related]
28. Nivolumab, an Anti-Programmed Cell Death-1 Antibody, Induces Fulminant Type 1 Diabetes.
Miyoshi Y; Ogawa O; Oyama Y
Tohoku J Exp Med; 2016 Jun; 239(2):155-8. PubMed ID: 27297738
[TBL] [Abstract][Full Text] [Related]
29. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
Wong JSL; Kwok GGW; Tang V; Li BCW; Leung R; Chiu J; Ma KW; She WH; Tsang J; Lo CM; Cheung TT; Yau T
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
[TBL] [Abstract][Full Text] [Related]
30. Immune checkpoint inhibitor-induced pure red cell aplasia: Case series and large-scale pharmacovigilance analysis.
Guo Q; Gao J; Guo H; Xie J; Cheng J
Int Immunopharmacol; 2023 Jan; 114():109490. PubMed ID: 36459923
[TBL] [Abstract][Full Text] [Related]
31. Successful treatment of nivolumab and ipilimumab triggered type 1 diabetes by using sodium-glucose transporter 2 inhibitor: a case report and systematic review.
Fujiwara M; Shimizu M; Okano T; Maejima Y; Shimomura K
Front Public Health; 2023; 11():1264056. PubMed ID: 38106883
[TBL] [Abstract][Full Text] [Related]
32. Type 1 diabetes mellitus affected by potential toxicity from long-term use of nivolumab.
Motomura Y; Urai S; Hirota Y; Takegawa N; Bando H; Yamamoto M; Fukuoka H; Tsuda M; Ogawa W
Diabetol Int; 2024 Jan; 15(1):130-134. PubMed ID: 38264226
[TBL] [Abstract][Full Text] [Related]
33. Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: a multicenter retrospective study.
Roessler D; Öcal O; Philipp AB; Markwardt D; Munker S; Mayerle J; Jochheim LS; Hammer K; Lange CM; Geier A; Seidensticker M; Reiter FP; De Toni EN; Ben Khaled N
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3065-3073. PubMed ID: 35864269
[TBL] [Abstract][Full Text] [Related]
34. Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors.
Gul A; Stewart TF; Mantia CM; Shah NJ; Gatof ES; Long Y; Allman KD; Ornstein MC; Hammers HJ; McDermott DF; Atkins MB; Hurwitz M; Rini BI
J Clin Oncol; 2020 Sep; 38(27):3088-3094. PubMed ID: 32491962
[TBL] [Abstract][Full Text] [Related]
35. Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency.
Manaka K; Sato J; Takeuchi M; Watanabe K; Kage H; Kawai T; Sato Y; Miyagawa T; Yamada D; Kume H; Sato S; Nagase T; Iiri T; Nangaku M; Makita N
Sci Rep; 2021 Jun; 11(1):11617. PubMed ID: 34078988
[TBL] [Abstract][Full Text] [Related]
36. Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report.
Appelbaum J; Wells D; Hiatt JB; Steinbach G; Stewart FM; Thomas H; Nghiem P; Kapur RP; Thompson JA; Bhatia S
J Immunother Cancer; 2018 Aug; 6(1):82. PubMed ID: 30170630
[TBL] [Abstract][Full Text] [Related]
37. Fulminant onset of insulin-dependent diabetes with positive anti-GAD antibody titers during treatment with nivolumab in a patient with NSCLC.
Matsuura N; Koh G; Konishi C; Minamino S; Takahara Y; Harada H; Kodama K; Emoto M
Cancer Immunol Immunother; 2018 Sep; 67(9):1417-1424. PubMed ID: 29995236
[TBL] [Abstract][Full Text] [Related]
38. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
[TBL] [Abstract][Full Text] [Related]
39. Fulminant Type 1 Diabetes Mellitus Accompanied by Positive Conversion of Anti-insulin Antibody after the Administration of Anti-CTLA-4 Antibody Following the Discontinuation of Anti-PD-1 Antibody.
Shiba M; Inaba H; Ariyasu H; Kawai S; Inagaki Y; Matsuno S; Iwakura H; Yamamoto Y; Nishi M; Akamizu T
Intern Med; 2018 Jul; 57(14):2029-2034. PubMed ID: 29491310
[TBL] [Abstract][Full Text] [Related]
40. Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.
Tan I; Malinzak M; Salama AKS
J Immunother Cancer; 2018 Jul; 6(1):77. PubMed ID: 30064495
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
